• By ICR Secretariat
  • Posted Wednesday, June 15, 2022

Regeneron's cholesterol drug war heats up with lawsuit over Amgen's 'illegal' bundling scheme


Since their PCSK9 drugs to lower bad cholesterol won FDA approvals a month apart in the summer of 2015, Amgen and Regeneron have waged a war for supremacy in the market—with the California-based drugmaker a decided winner.